D. E. Shaw & Co. Reports 5.1% Ownership in Keros Therapeutics, Inc.

D. E. Shaw & Co., L.P., D. E. Shaw & Co., L.L.C., and David E. Shaw have filed a Schedule 13G with the SEC, reporting a 5.1% ownership in Keros Therapeutics, Inc. The filing details the beneficial ownership of 1,545,948 shares of common stock, which includes shares managed by D. E. Shaw Valence Portfolios, L.L.C., D. E. Shaw Oculus Portfolios, L.L.C., and D. E. Shaw Investment Management, L.L.C. David E. Shaw, as the President and sole shareholder of D. E. Shaw & Co., Inc., and D. E. Shaw & Co. II, Inc., may be deemed to have shared power to vote or dispose of these shares. The filing includes certifications that the shares were not acquired for the purpose of influencing the control of the issuer. The filing also includes a joint filing agreement and powers of attorney for regulatory filings.